MNPR (Monopar Therapeutics) Net earnings per share growth this year

MNPR (Monopar Corp) - company brandmark

Monopar Therapeutics develops innovative radiopharmaceuticals, minimizing risks by targeting various types of solid tumors. The annual change in earnings per share confirms the asset's momentum, with the metric currently standing at -43.10. Future revenue is based on the patent protection of molecules, while sales potential relies on the colossal unmet demand of global oncology centers.

Earnings per share growth in current year: Monopar Therapeutics Inc (MNPR) for 07/04/2022 - 11/15/2026

Financial and market metric breakdowns for monopartx.com (MNPR)

Summary company analysis:MNPR Monopar Therapeutics
Signature product of Monopar Therapeutics

This indicator measures the year-over-year growth rate of earnings per share, allowing for an assessment of capital management efficiency and the speed of business recovery following market shocks. By analyzing the annual evolution of earnings per share, investors determine the entry point for Monopar Therapeutics (MNPR), whose valuation currently depends on the success of developing innovative radiopharmaceuticals for cancer therapy.

Key competitors

Earnings per share growth this year INCY|Earnings per share growth in current year Hutchison MediPharma|Net earnings per share growth this year nuvationbio.com (NUVB)|Earnings per share growth in current year Day One Biopharmaceuticals Inc (DAWN)|INBX - Earnings per share growth rate in current year|Earnings per share growth in current year I-Mab Inc. IMAB|Fennec - Earnings per share growth in current year|HRTX - Earnings per share growth in current year|Earnings per share growth rate in current year Nuvectis Pharma, Inc.|CHRS: Earnings growth in current year|Net earnings per share change in current year Corbus Pharma CRBP|Net earnings per share growth this year CRDF|Earnings per share growth rate in current year BeyondSpring Inc. BYSI|Net earnings per share growth this year BCAB (BioAtla Inc)|LIXT (Lixte Biotechnology Holdings, Inc.) - Earnings per share increase in current year|Citius Pharmaceuticals, Inc. - Net earnings per share growth this year|Net earnings per one share growth for the current year CLRB (Cellectar Biosciences, Inc.)|BioLineRx Corp - Earnings growth in current year|Earnings per share increase in current year CANF (Can-Fite BioPharma, Ltd.)|APRE: Earnings growth in current year|Earnings per share growth rate in current year Kazia (KZIA)|Earnings per share growth in current year silexion.com|NCNA: Earnings per share increase in current year|Earnings growth in current year CMRX|Earnings growth in current year Cyclacel, Inc. (CYCC)|Earnings per share growth in current year G1 Therapeutics Inc. GTHX|KRON (Kronos Bio) - Earnings per share trend in current year|KTRA: Net earnings per share growth this year|Earnings per share growth rate in current year Oncternal Therapeutics Inc|Portage Biotech (PRTG) - Earnings per share growth in current year